Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* -Written informed consent must be obtained before any assessment is performed.~* Male and female patients ≥ 18 years of age.~* Diagnosis of HS ≥ 1 year prior to baseline.~* Patients with moderate to severe HS defined as:~* A total of at least 5 inflammatory lesions, i.e. abscesses and/or inflammatory nodules AND~* Inflammatory lesions should affect at least 2 distinct anatomic areas~* Patients agree to daily use of topical over-the-counter antiseptics on the areas affected by HS lesions while on study treatment.~Exclusion Criteria:~* Total fistulae count ≥ 20 at baseline.~* Any other active skin disease or condition that may interfere with assessment of HS.~* Active ongoing inflammatory diseases other than HS that require treatment with prohibited medications.~* Use or planned use of prohibited treatment. Washout periods detailed in the protocol have to be adhered to.~* History of hypersensitivity to any of the study drug constituents.~* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or metastases (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 1 (Type: ACTIVE_COMPARATOR): Secukinumab 300mg every 2 weeks
- Secukinumab 2 (Type: ACTIVE_COMPARATOR): Secukinumab 300mg every 4 weeks
- Placebo 1 (Type: PLACEBO_COMPARATOR): Placebo group to secukinumab 300mg every 2 weeks
- Placebo 2 (Type: PLACEBO_COMPARATOR): Placebo group to secukinumab 300mg every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).